ライフサイエンスコーパス: yoelii

1 modium liver stages in vivo using Plasmodium yoelii.

2 and P. falciparum, and the liver stage of P. yoelii.

3 n was only critical in protection against P. yoelii.

4 I) of the rodent malaria parasite Plasmodium yoelii.

5 parum, and its rodent-infectious relative, P.yoelii.

6 in vivo using the rodent parasite Plasmodium yoelii.

7 ALB/c mice were solidly protected against P. yoelii.

8 mily exist in the rodent parasite Plasmodium yoelii.

9 ed in the murine malaria parasite Plasmodium yoelii.

10 )) of the murine malaria parasite Plasmodium yoelii.

11 and subsequent resistance to infection by P. yoelii.

12 ABA diets do not die from lethal doses of P. yoelii.

13 on from challenge with a lethal strain of P. yoelii.

14 s and the rodent malaria parasite Plasmodium yoelii.

15 andidiasis or initial hepatic invasion by P. yoelii.

16 plexans Plasmodium falciparum and Plasmodium yoelii.

17 ll up-regulated 24 h after infection with P. yoelii.

18 ic characterization of PanK1 and PanK2 in P. yoelii.

19 alaria parasites, Plasmodium chabaudi and P. yoelii.

20 r numbers in response to coinfection with P. yoelii.

21 artemisinin in the rodent malaria Plasmodium yoelii.

22 eting techniques to delete PAT in Plasmodium yoelii.

23 3) in the rodent malaria parasite Plasmodium yoelii.

24 y spleen macrophages and DCs from Plasmodium yoelii 17NXL-infected and P. berghei ANKA-infected mice.

25 re, we test chemically attenuated Plasmodium yoelii 17X and demonstrate significant protection follow

26 PyMIF were generated, one in a nonlethal P. yoelii 17X background [Py17X-MIF(+)] and the other in a

27 ge infection with reticulocyte-restricted P. yoelii 17X parasites.

28 d do not suppress the growth of nonlethal P. yoelii 17X, a parasite that primarily replicates in reti

29 ponse to infection with nonlethal Plasmodium yoelii 17X.

30 d survival compared to mice infected with P. yoelii 17XL alone.

31 tible than C57BL/6 mice to infection with P. yoelii 17XL and were not protected against lethal malari

32 us alum and challenged intravenously with P. yoelii 17XL asexual blood-stage parasites.

33 [Py17X-MIF(+)] and the other in a lethal P. yoelii 17XL background [Py17XL-MIF(+)].

34 ecific antibodies preferentially suppress P. yoelii 17XL growth in mature erythrocytes compared to gr

35 with M. tuberculosis CDC1551 and Plasmodium yoelii 17XL had a lower peak parasitemia and increased s

36 nearly complete protection against lethal P. yoelii 17XL malaria.

37 been shown to protect mice against lethal P. yoelii 17XL malaria.

38 ene expression in reticulocyte-restricted P. yoelii 17XL parasites that escaped neutralization by PyM

39 lly prominent 5 days after infection with P. yoelii 17XL.

40 in BALB/c mice subsequently infected with P. yoelii 17XL.

41 lated to protection from a challenge with P. yoelii 17XL.

42 ow that co-infection of mice with Plasmodium yoelii 17XNL (Py17XNL) and Salmonella enterica serovar T

43 growth and survival of nonlethal Plasmodium yoelii 17XNL (PyNL) malaria in C57BL/6 mice.

44 lum of P. yoelii YM and to challenge from P. yoelii 17XNL, another strain.

45 nous, Plasmodium berghei ANKA- or Plasmodium yoelii 17XNL-parasitized red blood cells (pRBCs) after t

46 and amino acid homology with the Plasmodium yoelii 235-kDa rhoptry protein family, which is also rel

47 althy RBCs and RBCs infected with Plasmodium yoelii, a commonly studied rodent parasite model.

48 gly reduced in mice infected with Plasmodium yoelii, a rodent malaria model.

49 tic machinery to synthesize PABA, Plasmodium yoelii, a rodent malaria species, requires exogenous die

50 Two candidate Plasmodium yoelii adhesion proteins are apical membrane antigen 1 (

51 circumsporozoite (CS) protein of Plasmodium yoelii (AdPyCS), followed by a booster with an attenuate

52 al pathogens Candida albicans and Plasmodium yoelii, an accepted experimental malaria model in mouse.

53 tage by using the rodent malaria parasite P. yoelii, an important model for malaria vaccine developme

54 f a linear peptide construct specific for P. yoelii and compared the responses of antigen-presenting

55 s expressed in the gametocytes of Plasmodium yoelii and identify that GEP1 is required for XA-stimula

56 Rodent malaria species Plasmodium yoelii and P. chabaudi have been widely used to validate

57 eased in vivo and in vitro during Plasmodium yoelii and P. falciparum intrahepatic development.

58 cells (RBC) of all ages (RBC generalist); P. yoelii and P. vivax preferentially infect young RBCs (RB

59 g TMP-SMX effects on the rodent parasites P. yoelii and Plasmodium berghei and on the human malaria p

60 es of the rodent malaria parasite Plasmodium yoelii and studied the early events in the development o

61 nt extracts and Hz from P. falciparum and P. yoelii and synthetic Hz suppressed Epo-induced prolifera

62 kDa family of rhoptry proteins in Plasmodium yoelii and the two reticulocyte binding proteins of P. v

63 luding P. vivax, P. knowlesi, P. berghei, P. yoelii, and P. chabaudi.

64 ithin sequenced chitinases of P. berghei, P. yoelii, and P. gallinaceum (PgCHT1).

65 We use the rodent malaria P. yoelii, and somatically transinfected An. stephensi as a

66 re features of malarial anemia in Plasmodium yoelii- and Plasmodium berghei ANKA-infected mice, simil

67 lasmid DNA encoding preerythrocytic-stage P. yoelii antigens.

68 odent models of malaria, commonly Plasmodium yoelii, are frequently used for studies of malaria patho

69 nnotated genes will facilitate the use of P. yoelii as a model system for studying human malaria.

70 redicted interactions is observed against P. yoelii, because of missing ortholog partners in pairs of

71 circumsporozoite protein (CS) of Plasmodium yoelii between 17D nonstructural proteins NS2B and NS3.

72 tein-1 protein vaccines against a Plasmodium yoelii blood-stage challenge.

73 Targeted deletion of SAP1 in Plasmodium yoelii caused the depletion of a number of selectively t

74 plete protection against a lethal Plasmodium yoelii challenge in mice.

75 We have reported a Plasmodium yoelii chimeric multistage recombinant protein (P. yoeli

76 g a B cell epitope derived from a Plasmodium yoelii circumsporozoite (CS) protein (referred to as the

77 g vaccine constructs based on the Plasmodium yoelii circumsporozoite protein (CSP) and P. yoelii mero

78 DNA vaccine plasmids encoding the Plasmodium yoelii circumsporozoite protein (PyCSP) and murine granu

79 nized as neonates (7 days) with a Plasmodium yoelii circumsporozoite protein (PyCSP) DNA vaccine mixe

80 r a recombinant adenovirus expressing the P. yoelii circumsporozoite protein in mice.

81 racterized protective plasmid encoding P. y. yoelii circumsporozoite protein.

82 ected with a non-lethal strain of Plasmodium yoelii Compared with Cd36(-/-) mice, WT mice had lower p

83 A synteny map of 2,212 P. y. yoelii contiguous DNA sequences (contigs) aligned to 14

84 of WT/CS-GFP, a recombinant Ad expressing P. yoelii CS protein and GFP as its transgene.

85 ntaining PyCS-B epitope in the HVR1 and a P. yoelii CS transgene was maintained.

86 P. knowlesi CSP (PkCSP) and P. yoelii CSP (PyCSP) had 4,790- and 17,800-fold lower affi

87 Passive transfer of a P. yoelii CSP MAb showed inhibition of liver infection when

88 Furthermore, P. yoelii Deltamif parasites exhibited growth retardation i

89 P. yoelii Deltamif parasites grew normally as asexual eryth

90 Mice infected with P. yoelii Deltamif sporozoites either did not develop blood

91 In contrast, the P. yoelii Deltamif strain was attenuated during the liver s

92 we generated a Py-mif knockout parasite (P. yoelii Deltamif).

93 eneralist facilitates the RBC specialist (P. yoelii density is enhanced ~10 fold).

94 ation of mice with yeast-secreted Plasmodium yoelii-derived 19-kilodalton merozoite surface protein 1

95 hether Hz contributes to malarial anemia, P. yoelii-derived or synthetic Hz was administered to naive

96 r the circumsporozoite protein of Plasmodium yoelii develop a severely impaired memory response after

97 dependent blocking effect against Plasmodium yoelii development in An. stephensi.

98 tion by PyMSP-8-specific antibodies using P. yoelii DNA microarrays.

99 important for liver-stage development of P. yoelii, during which it is likely to play an intrinsic r

100 Infection of mice with Plasmodium yoelii elicited infiltration of inflammatory macrophages

101 n agreement with the presence of genes in P. yoelii encoding for proteins with homology to NADH-Q oxi

102 d that during the acute phases of Plasmodium yoelii erythrocyte stage infection, APC upregulate the e

103 dentification method approach used 192 P. y. yoelii exons from genes expressed during the sporozoite

104 imental immunization of mice with Plasmodium yoelii fabb/f(-) (Pyfabb/f(-)), a genetically attenuated

105 induced by immunization with the Plasmodium yoelii fabb/f(-) genetically attenuated parasite.

106 Here using P. yoelii, for the first time we provide a proteomic compar

107 We show that P. yoelii GAPs reach the liver, invade hepatocytes, and dev

108 Here we show that a P. yoelii gene encoding a HECT-like E3 ubiquitin ligase (Py

109 We disrupted the Plasmodium yoelii gene encoding high mobility group nuclear factor

110 P1 in the rodent malaria parasite Plasmodium yoelii generated mutant parasites that traverse and inva

111 Orthologs of protective P. y. yoelii genes can then be identified in the genomic datab

112 tified and manually curated a further 510 P. yoelii genes which have clear orthologs in the P. falcip

113 sterile protection conferred by a Plasmodium yoelii genetically attenuated parasite (PyGAP) vaccine w

114 suggests that improvements of the current P. yoelii genome annotation should focus on genes expressed

115 ry and matching the cDNA sequences to the P. yoelii genome yielded 25 redundantly tagged genes includ

116 The sequencing of the Plasmodium yoelii genome, a model rodent malaria parasite, has grea

117 ch shows that apicoplast-targeted Plasmodium yoelii glycerol 3-phosphate dehydrogenase and glycerol 3

118 Our results suggest that P. yoelii has an incomplete apicoplast-targeted phosphatidi

119 n the murine malaria model system Plasmodium yoelii has been cumbersome and requires terminal procedu

120 rozoites of Plasmodium berghei or Plasmodium yoelii has been used extensively to evaluate liver-stage

121 The low 50% infectious dose of P. yoelii in BALB/c mice provides the most sensitive infect

122 rial activity against multidrug-resistant P. yoelii in mice in the dose range of 5-100 mg/kg x 4 days

123 tic antimalarial activity against Plasmodium yoelii in mouse by oral administration.

124 Plasmodium berghei, and absent in Plasmodium yoelii In Plasmodium knowlesi, telomeres and virulence g

125 ivity against multidrug-resistant Plasmodium yoelii in Swiss mice by oral route.

126 route against multidrug-resistant Plasmodium yoelii in Swiss mice.

127 rray analysis of CD4(+) T cells following P. yoelii-induced exhaustion shows upregulation of effector

128 ction and are therefore more resistant to P. yoelii-induced exhaustion than their wild-type counterpa

129 us protein 14K (A27) to the CS of Plasmodium yoelii, induces strong effector memory CD8(+) T cell res

130 -specific memory CD8 T cell protection in P. yoelii-infected BALB/c or P. berghei-infected B10.D2 mic

131 fic ablation of Foxp3(+) Tregs in Plasmodium yoelii-infected DEREG-BALB/c mice leads to an increase i

132 s for their capacity to eliminate Plasmodium yoelii-infected hepatocytes.

133 in vivo and cleared malaria from Plasmodium yoelii-infected mice, resulting in 100% mice survival ra

134 l-derived IFN-gamma production in Plasmodium yoelii-infected mice.

135 ivo in Plasmodium berghei- and/or Plasmodium yoelii-infected mice.

136 n of effector cytokines following Plasmodium yoelii infection and are therefore more resistant to P.

137 e changes suggest the immune responses to P. yoelii infection are both parasite and organ specific.

138 4(+)Foxp3(+) Tregs modulate the course of P. yoelii infection in BALB/c mice.

139 nto mature B cells in response to Plasmodium yoelii infection in mice.

140 its PfPSD activity and eliminates Plasmodium yoelii infection in mice.

141 ple and noninvasive method for monitoring P. yoelii infection in the liver provides an efficient syst

142 ysis of cytokine production revealed that P. yoelii infection induced two distinct peaks of IFN-gamma

143 om uninfected mosquitoes prior to Plasmodium yoelii infection influences the local and systemic immun

144 initiation of a PABA-deficient diet after P. yoelii infection is established leads to the clearance o

145 In our experiments, Plasmodium yoelii infection led to a reduced CD8(+) T cell response

146 Remarkably, P. yoelii infection reduced colonization resistance of mice

147 phenotypic changes in DCs during Plasmodium yoelii infection represent a mechanism of controlling ho

148 in promoting the establishment of Plasmodium yoelii infection through delayed clearance of parasitemi

149 /6 mice show comparable susceptibility to P. yoelii infection with sporozoites and that bioluminescen

150 During a Plasmodium yoelii infection, these regulatory CD11clowCD45RBhigh DC

151 These results show that P. yoelii infection, via alterations to the microbial commu

152 on of TLR3-dependent pathway early during P. yoelii infection.

153 ere the primary producers of CXCL12 after P. yoelii infection.

154 s (DARC), have different susceptibility to P yoelii infection.

155 altered during the liver stage of Plasmodium yoelii infection.

156 oughout the course of blood-stage Plasmodium yoelii infection.

157 )CD25(-)Foxp3(-) T cells in the course of P. yoelii infection.

158 or T cells as the main mechanism, because P. yoelii infections did not suppress the recruitment or pr

159 Our results suggest that P. yoelii infections suppress immunity to Listeria by causi

160 ure erythrocytes) had negligible levels of P yoelii invasion compared with wild-type normocytes, demo

161 to identify the role of the murine DARC in P yoelii invasion.

162 cterium-induced protection against lethal P. yoelii is mouse strain specific.

163 rotein PY01515 (PDB ID 2aqw) from Plasmodium yoelii, it is shown that the putative annotation, Orotid

164 identified the pyp140 gene by screening a P. yoelii lambda-Zap cDNA expression library.

165 chimeric multistage recombinant protein (P. yoelii linear peptide chimera/recombinant modular chimer

166 sites allows for quantitative analysis of P. yoelii liver stage burden and parasite development, whic

167 es host kinases, which facilitate Plasmodium yoelii liver stage infection.

168 a showed NNRTI treatment modestly reduced P. yoelii liver stage parasite burden and minimally extende

169 lethal and nonlethal blood stage Plasmodium yoelii malaria infections.

170 e protection against normocyte-associated P. yoelii malaria parasites is mediated by antibodies that

171 Immunization with Plasmodium yoelii merozoite surface protein (PyMSP)-8 protects mice

172 r the C-terminal 19-kDa region of Plasmodium yoelii merozoite surface protein 1 (MSP119), a major tar

173 SP1(1)(9) (PyMSP1(1)(9)) with full-length P. yoelii merozoite surface protein 8 (MSP8).

174 yoelii circumsporozoite protein (CSP) and P. yoelii merozoite surface protein-1 (MSP-1) showed encour

175 Immunization with Plasmodium yoelii merozoite surface protein-8 (PyMSP-8) has been sh

176 P. yoelii MIF (Py-MIF) was expressed in blood-stage parasit

177 ised against purified, non-epitope-tagged P. yoelii MIF (PyMIF) were used to localize expression in t

178 porozoite challenge in the rodent Plasmodium yoelii model.

179 o interact with the amino-terminal end of P. yoelii MSP-1 in a yeast two-hybrid system.

180 smodium yoelii sequence-related molecules P. yoelii MSP-7 (merozoite surface protein 7) and P. yoelii

181 These results establish that both P. yoelii MSP-7 and P. yoelii MSRP-2 are expressed on the s

182 the rodent system demonstrated that both P. yoelii MSP-7 and P. yoelii MSRP-2 could be isolated from

183 Immunofluorescence studies colocalized P. yoelii MSP-7 and P. yoelii MSRP-2 with the amino-termina

184 mmunization with P. yoelii MSRP-2 but not P. yoelii MSP-7 protected mice against a lethal infection w

185 del, we tested the ability of recombinant P. yoelii MSP-8 (rPyMSP-8) to complement rPyMSP-1-based vac

186 Plasmodium yoelii murine model, we fused P. yoelii MSP1(1)(9) (PyMSP1(1)(9)) with full-length P. yoe

187 i MSP-7 (merozoite surface protein 7) and P. yoelii MSRP-2 (MSP-7-related protein 2) by their ability

188 s establish that both P. yoelii MSP-7 and P. yoelii MSRP-2 are expressed on the surface of merozoites

189 Immunization with P. yoelii MSRP-2 but not P. yoelii MSP-7 protected mice aga

190 emonstrated that both P. yoelii MSP-7 and P. yoelii MSRP-2 could be isolated from parasite lysates an

191 s and released from the parasite and that P. yoelii MSRP-2 may be the target of a protective immune r

192 e studies colocalized P. yoelii MSP-7 and P. yoelii MSRP-2 with the amino-terminal portion of MSP-1 a

193 administration in an erythrocytic Plasmodium yoelii murine malaria model; (3) prevention of in vitro

194 We used the Plasmodium yoelii murine model to study the potential role of paras

195 Previously, using the Plasmodium yoelii murine model, we fused P. yoelii MSP1(1)(9) (PyMS

196 n proof-of-concept studies in the Plasmodium yoelii murine model, we produced a chimeric vaccine anti

197 to infections with two strains of Plasmodium yoelii (N67 and N67C) and discovered differences in inna

198 ivity against multidrug-resistant Plasmodium yoelii nigeriensis in Swiss mice.

199 l showed that 5 days after coinoculation, P. yoelii nigeriensis infection increased the recovery of S

200 C57BL/6 mice infected with Plasmodium yoelii nigeriensis N67C display high levels of pro-infla

201 Infection with P. yoelii nigeriensis, but not antibody-mediated hemolysis,

202 se data suggested that both hemolysis and P. yoelii nigeriensis-specific factors contributed to the i

203 m challenge in mice infected with Plasmodium yoelii nigeriensis.

204 n reading frame (ORF) of PY02159 from the P. yoelii NL genome sequencing project.

205 ) CD4(+) T cell exhaustion during Plasmodium yoelii nonlethal infection occurs alongside the reductio

206 activity of 1.6 and 3.7 mg/kg against the P. yoelii NS strain compared to 7.9 and 7.4 mg/kg for amodi

207 Knockout of PlasMei2 (plasmei2(-)) in P. yoelii only affected late liver stage development.

208 (beta2M-/-) mice with irradiated Plasmodium yoelii or P. berghei sporozoites.

209 Here, we show that the Plasmodium yoelii orthologs of four Plasmodium falciparum proteins

210 ith its Plasmodium falciparum and Plasmodium yoelii orthologs, respectively.

211 0 P. falciparum genes, more than 3,300 P. y. yoelii orthologues of predominantly metabolic function w

212 es infecting rodents, monkeys and humans (P. yoelii, P. berghei, P. chabaudi, P. knowlesi and P. viva

213 tion and characterization of a transgenic P. yoelii parasite expressing the reporter protein lucifera

214 ozoites in both rodent-infectious Plasmodium yoelii parasites and human-infectious Plasmodium falcipa

215 e, we generated p52/p36-deficient Plasmodium yoelii parasites by the simultaneous deletion of both ge

216 Infection of mice with strains of Plasmodium yoelii parasites can result in different pathology, but

217 form are highly effective against Plasmodium yoelii parasites in mice and against Plasmodium falcipar

218 We show that P. yoelii parasites lacking either PanK1 or PanK2 undergo n

219 P. yoelii parasites lacking PNP were attenuated and cleared

220 ice born of mothers previously exposed to P. yoelii parasites or immunized with the vaccine were prot

221 ilities to resist hepatic accumulation of P. yoelii parasites.

222 ion of the E1alpha or E3 subunit genes of P. yoelii PDH caused no defect in blood stage development,

223 e E1 alpha or E3 subunit genes of Plasmodium yoelii PDH caused no defect in blood stage development,

224 Epitope-tagged Plasmodium yoelii PlasMei2 was expressed only during liver stage sc

225 However, P. yoelii plasmei2(-) liver stage schizonts exhibited an ab

226 The P. yoelii plasmei2(-) liver stage size increased progressiv

227 Consequently the cellular integrity of P. yoelii plasmei2(-) liver stages became increasingly comp

228 This resulted in a complete block of P. yoelii plasmei2(-) transition from liver stage to blood

229 d late in development and the majority of P. yoelii plasmei2(-) underwent cell death by the time wild

230 cByJ mice are more susceptible to Plasmodium yoelii preerythrocytic infection than BALB/cJ mice.

231 d approach of developing chimeric Plasmodium yoelii proteins to enhance protective efficacy, we desig

232 Green fluorescent protein-tagged Plasmodium yoelii (PyGFP) was used to efficiently isolate LS-infect

233 the 60-kDa heat shock protein of Plasmodium yoelii (PyHsp60) was cloned into the VR1012 and VR1020 m

234 Plasmodium falciparum (PfMIF) and Plasmodium yoelii (PyMIF)) non-competitively in a reversible fashio

235 P. yoelii-related host gene changes were compared with thos

236 nt CD4(+) T cells into mice infected with P. yoelii results in increased production of antibodies to

237 omes of Plasmodium falciparum and Plasmodium yoelii revealed a conserved core of 4500 Plasmodium gene

238 ce infected with malaria-inducing Plasmodium yoelii revealed that chloroquine treatment could lead to

239 of the UIS3 and UIS4 loci in the Plasmodium yoelii rodent malaria model (Pyuis3[-] and Pyuis4[-]).

240 ty and efficacy studies using the Plasmodium yoelii rodent model, we tested the ability of recombinan

241 ization with recombinant CSP from Plasmodium yoelii (rPyCSP), when delivered in Montanide ISA 51, ind

242 ubtractive hybridization (SSH) of Plasmodium yoelii salivary gland sporozoites versus merozoites to i

243 we described the isolation of the Plasmodium yoelii sequence-related molecules P. yoelii MSP-7 (meroz

244 ciparum, P. gallinaceum, P. knowlesi, and P. yoelii species representing human, avian, simian, and ro

245 w that dendritic cells presenting Plasmodium yoelii sporozoite antigens are able to activate specific

246 cells are required for protection against P. yoelii sporozoite challenge than for protection against

247 erum with a luciferase-expressing Plasmodium yoelii sporozoite challenge to assess Ab-mediated inhibi

248 om naive mice that had survived wild-type P. yoelii sporozoite infection targeted mainly sporozoite-t

249 n the BALB/c mouse model of P. berghei or P. yoelii sporozoite infection to examine the role of immun

250 of human Plasmodium falciparum and rodent P. yoelii sporozoite infectivity, CD81 may also play a vita

251 using mice singly immunized with Plasmodium yoelii sporozoites and high-throughput screening, we ide

252 assays reveal that Plasmodium berghei and P. yoelii sporozoites attach to and enter Kupffer cells, bu

253 to 2 days prior to challenge with Plasmodium yoelii sporozoites conferred sterile protection against

254 CD8+ T cells induced by Plasmodium yoelii sporozoites develop into protective memory cells

255 duce sterile protection from challenge by P. yoelii sporozoites in the absence of T cells in 50% of m

256 ministered with either irradiated Plasmodium yoelii sporozoites or a recombinant adenovirus expressin

257 by immunization with radiation-attenuated P. yoelii sporozoites or with plasmid DNA encoding preeryth

258 In BALB/c mice, repeated small doses of P. yoelii sporozoites progressively expand the population o

259 n against the experimental challenge with P. yoelii sporozoites than passive immunization with purifi

260 d 2 weeks later with 2 x 10(3) irradiated P. yoelii sporozoites, and were challenged several weeks la

261 not from vector control groups recognized P. yoelii sporozoites, liver stages, and infected erythrocy

262 ia in immunized mice challenged with live P. yoelii sporozoites, revealing an adjuvant activity for D

263 Following immunization with Plasmodium yoelii sporozoites, the CD8(+) T cell population specifi

264 and radiation-attenuated (IrrSpz) Plasmodium yoelii sporozoites.

265 ic activity in mice infected with Plasmodium yoelii sporozoites.

266 mice immunized with either P. berghei or P. yoelii sporozoites.

267 were protected against challenge with 50 P. yoelii sporozoites.

268 mmunization, mice were challenged with 50 P. yoelii sporozoites.

269 cted mice against a lethal infection with P. yoelii strain 17XL.

270 me rodent malaria parasites, like Plasmodium yoelii strain 17XNL (Py17XNL), induce a transient (self-

271 time of Swiss mice infected with Plasmodium yoelii (strain N-67).

272 propose an alternative mechanism whereby P. yoelii suppresses Listeria-specific T cell responses.

273 f mice with Plasmodium berghei or Plasmodium yoelii synthetic linear peptide chimeras (LPCs) based on

274 haracterized the MIF homologue of Plasmodium yoelii throughout the life cycle, with emphasis on preer

275 of three apicomplexan pathogens--Plasmodium yoelii, Toxoplasma gondii, and Cryptosporidium parvum--d

276 d for both Plasmodium berghei and Plasmodium yoelii, two different rodent malaria parasites, suggesti

277 n the circumsporozoite protein of Plasmodium yoelii was delivered to DCs.

278 rcumsporozoite protein (PyCSP) of Plasmodium yoelii was engineered into a T. gondii temperature-sensi

279 nt malaria models (Plasmodium berghei and P. yoelii), we were unable to show that saliva had any dete

280 of mice were similarly protected against P. yoelii, we could not correlate vaccine-induced responses

281 el mimicking natural infection by Plasmodium yoelii, we delineated early events governing the develop

282 Using rodent-infectious Plasmodium yoelii, we demonstrate that both gene disruptions and co

283 and MyD88(-/-) mice infected with Plasmodium yoelii, we show that TLR9 and MyD88 regulate pro/anti-in

284 rs from Plasmodium falciparum and Plasmodium yoelii, which likely diverged >or=100 million years ago

285 Previously, we identified a Plasmodium yoelii YM 140-kDa merozoite protein, designated PyP140,

286 virulence loci using the offspring from a P. yoelii YM and N67 genetic cross, and identify a putative

287 sequent challenge to a lethal inoculum of P. yoelii YM and to challenge from P. yoelii 17XNL, another

288 ng but failed to protect against a lethal P. yoelii YM infection.

289 erum and were resistant to lethal plasmodium yoelii YM infection.

290 We created a P. yoelii YM strain (PyLuc) that stably expresses firefly l

291 e gene encoding PNP in the lethal Plasmodium yoelii YM strain.

292 against a lethal challenge infection with P. yoelii YM.

293 These results suggest that P. yoelii yoelii 17XNL infection induces the production of

294 and MCP-1/CCL2 were detected early after P. yoelii yoelii 17XNL infection.

295 ly in the rodent malaria parasite Plasmodium yoelii yoelii code for 235-kilodalton proteins (Py235) t

296 vaccines encoding exons from the Plasmodium yoelii yoelii genomic sequence.

297 hosphorylation of mitochondria of Plasmodium yoelii yoelii trophozoites were assayed in situ after pe

298 shotgun sequence of one species, Plasmodium yoelii yoelii, and comparative studies with the genome o

299 amilies in both P. falciparum and Plasmodium yoelii yoelii, where no orthologs were predicted uniquel

300 C57BL/6J mice were infected with Plasmodium yoelii yoelli 17XNL, and blood and tissues were collecte